Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Status:
Terminated

Trial end date:
2009-12-22

Target enrollment:

Participant gender:

This study will confirm safety and tolerability and determine the MTD of BGT226 in Japanese patients with advanced solid tumor.

Phase 1

Novartis Pharmaceuticals